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A B S T R A C T
Cardiolipin (CL) and b2-Glycoprotein I (b2-GpI) antibodies have been shown to associate with various
neurological symptoms including seizures and cognitive dysfunction. Here we studied the prevalence of
CL, b2-GpI and antinuclear (ANA) antibodies in 74 patients with various developmental disorders with
epilepsy and 70 healthy controls. Developmental disorders were classiﬁed into genetic syndromes and
diseases, genetic and/or acquired conditions, cortical dysgenesias and acquired encephalopathias. IgM-
CL andb2-GpI antibodieswere signiﬁcantlymore common in patients (46% vs. 20%, p < 0.001 and 10% vs.
0%, p < 0.05). Patients with most frequent seizures were more likely to have IgM-CL antibodies. The risk
for positive IgM-CL, IgG-CL and b2-GpI antibodies increased concomitantly with increasing intellectual
disability. Present data demonstrates that epilepsy with frequently recurring seizures may be associated
with secondary immune system activation.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Phospholipid (PL) antibodies are a heterogeneous group of
autoantibodies binding to phospholipid-like antigens like cardi-
olipin (CL) and phosphatidylserine (PS).b2-Glycoprotein I (b2-GpI)
is a plasma protein binding to negatively charged macromolecules
and structures, such as phospholipids, DNA, platelets and
mitochodria.1 b2-GpI mRNA is also expressed in neurons,
astrocytes and in brain endothelial cells.2 Phospholipid and b2-
GpI antibodies have reported to bind to neuronal tissue.3–6
High systemic titres of these antibodies are characteristic to
primary antiphospholipid syndrome (APS), with systemic mani-
festations of recurrent spontaneous pregnancy loss, thrombosis,
thrombocytopenia, aswell as various central nervous system (CNS)
symptoms.7 These neurological symptoms include chorea, psy-
chosis, depression, cognitive dysfunction and dementia.7,8 Seizures
are relatively well characterized neurological symptoms associat-
ed with PL antibodies, especially in patients with systemic lupus
erythematosus (SLE).9,10 However, PL antibodies have been found
in patients with epilepsy without SLE.11–13* Corresponding author. Tel.: +358 331169412; fax: +358 331164373.
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1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.01.018In the present study we aimed to study the role of CL, b2-GpI
and antinuclear (ANA) autoantibodies in different types of
developmental disorders. We have especially focused on whether
these antibodies are associated with the level of cognitive
dysfunction, etiological factors underlying intellectual disability
and epilepsy, speciﬁc epilepsy syndromes or frequency of seizures.
2. Materials and methods
The inclusion criteria for the study were a developmental
disorder due to a genetic or structural cause with at least ﬁve-year
history of refractory seizures despite of adequate treatment. Of 77
consecutively recruited patients, written informed consent was
obtained from guardians of 74 patients. A total of 70 healthy blood
donors were used as control subjects.
The patients’ blood sampleswere taken in connection to routine
laboratory tests. We used commercially available assays to
determine CL antibody titres (Quanta Lite ACA IgG and IgM; B2
GPI, IgG; INOVA Diagnostics, San Diego, CA, USA). Patients and
controls with positive results in IgG-CL assay were also tested for
distinct IgG class b2-GpI antibodies. Antinuclear (ANA) antibodies
were measured indirectly using Hep-2 cells as antigens (INOVA
Diagnostics, San Diego, CA, USA), and presence of antibodies were
determined using ﬂuoromicroscopy. The limit values between
positive and negative results were 12.5 international MPL units for
IgM-CL antibodies; 15 international GPL units for IgG-CL anti-
bodies, and 20 international SGU units for b2-GpI antibodies.vier Ltd. All rights reserved.
Table 1
Etiological groups and speciﬁc diagnoses of the 74 study patients.
Etiological groups Diagnosis
Genetic syndromes (15) Down syndrome (4), X-linked mental retardation (3), trisomy 15q (2), Angelman (1), deletion 6q (1), autosomal dominant
familial disorder (1), Kabuki (1), unidentiﬁed dysmorphic syndrome (2)
Genetic diseases (7) Aspartylglucosaminuria (2), spinocerebellar ataxia (1), neuroﬁbromatosis type 2 (1), MELAS (1), x-linked familial (1),
Dravet (1)
Genetic/acquired condition (6) Infantile autism (4), unspeciﬁc intellectual disability with generalized epilepsy (2)
Cortical dysgenesias (15) Polymicrogyria (6), temporal dysmyelination (4), microcephalia (2), schizenkefalia (1), pachygyria (1), lissenencephalia (1)
Acquired encephalopathias (31) post-asphyxial (11), post-infectious (8), mesial temporal sclerosis (5), early severe epilepsy (4) and post-traumatic (3)
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regression analysis served in statistical analysis. A p value of
0.05 or less was considered statistically signiﬁcant. The ethical




The study group comprised of 74 patients (31 females and 43
males, age range 15–61, mean age 35 years) and 70 controls (age
range 16–65 years, mean age 36 years). All patients had undergone
a detailed analysis of their condition including video-EEG, brain
MRI aswell as consultation of a clinical geneticist and psychologist.
The patients’ etiological diagnoses in detail (classiﬁed into genetic
syndromes, genetic diseases, genetic and/or acquired conditions,
cortical dysgenesias and acquired disorders) are presented in Table
1 and epilepsy diagnoses in Table 2. Sixty-four patients (86%)
experienced ﬁrst seizures during childhood or adolescence. Twelve
patients showed hippocampal sclerosis (eight had an acquired
encephalopathia and four a genetic disorder) in brain MRI. Two
patients acted at subnormal intelligence, 7 at the level of mild (IQ
69–50), 4 at moderate (IQ 49–35), 30 at severe (IQ 34–20), and 31
at the level of profound (IQ < 20) intellectual disability (ID). Nine
patients suffered from 1 to 11 seizures yearly, 27 from 1 to 3
seizures monthly, 21 from 1 to 6 seizures weekly, and 17 patients
from daily seizures.
All patients except one were on polytherapy. Fifty-ﬁve patients
received valproate, 28 topiramate, 25 lamotrigine, 16 oxcarbatse-
pine, 10 levetirasetame, 9 carbamazepine, 9 clobatsame, 8Table 2
Prevalence of positive antibodies in controls and patients according to etiology and ep
IgM-CL (%)
Controls (n=70) 14 (20)
All patients (n=74) 34 (46)***
Etiology
Genetic syndrome (n=15) 5 (33)
Genetic disease (n=7) 3 (43)
Genetic/acquired condition (n=6) 2 (33)
Cortical dysgenesias (n=15) 7 (47)
Acquired encephalopathia (n=31) 17 (55)
Epilepsy syndrome
Lennox-Gastaut syndrome (n=18) 12 (67)
CSWSS (n=4) 0
Generalized epilepsy (degenerative) (n=6) 2 (33)
Generalized epilepsy (idiopathic) (n=5) 0
TLE with HS (n=12) 5 (42)
Extra-TLE focal/multifocal epilepsy (n=26) 12 (44)
Reﬂex epilepsy (n=1) 1
Infantile spasms (n=1) 1
Dravet syndrome (n=1) 1
Abbreviations: Ab, antibody; ANA, antinuclear antibody; CL, cardiolipin; CSWSS, continu
hippocampal sclerosis; IgG, immunoglobulin class G; IgM, immunoglobulin class M; TL
Statistical difference between patients and controls: *** (p<0,001), and * (p<0,05; Fisclonazepam, 7 vigabatrine, 6 gabapentine, 5 phenytoin, 2
ethosuximide, 2 azetatsolamide, and 2 phenobarbitale.
3.2. Antibody tests
3.2.1. Patients and controls
Positive titres of IgM-CL antibodies were more frequent in
patients (46%) than in controls (20%) (p < 0.001; Fisher’s exact test,
Table 2). The prevalence of positive IgG-CL antibodies did not differ
between patients (16%) and controls (13%), however, 10% of
patients had b2-GpI antibodies while no b2-GpI antibodies were
detected in controls (p < 0.05; Fisher’s exact test, Table 2). The
prevalence of ANA antibodies was the same among patients and
controls. The patient’s age, gender, onset age of epilepsy or
medication did not relate to the prevalence of PL or ANA
antibodies.
3.2.2. Etiology of developmental disorder
The prevalence of positive antibody titres in different etiologi-
cal groups is presented in Table 2. Autoantibodieswere not speciﬁc
to any of the etiological groups, but were distributed within all
groups studied. The prevalence of positive antibodies was highly
dependent of the number of patients in each group (Table 2).
3.2.3. Epilepsy syndrome and seizure frequency
Autoantibodies studied were not speciﬁc to any of the epileptic
syndromes. There were no statistically signiﬁcant differences
between epileptic syndromes, although IgM-CL antibodies were
most frequent in Lennox-Gastaut syndrome (Table 2). Prevalence
of antibodies was highly dependent of the group size. We found no
association between positive antibodies and presence of hippo-ilepsy syndrome.
IgG-CL (%) b2-GpI (%) ANA (%)
9 (13) 0 8 (11)
12 (16) 7 (10)* 8 (11)
4 (27) 1 (7) 0
1 (14) 1 (14) 0
0 0 1 (17)
1 (7) 1 (7) 1 (7)
6 (19) 4 (13) 6 (19)
4 (22) 2 (11) 4 (22)
0 0 0
2 (33) 0 0
0 0 0
2 (17) 1 (8) 2 (17)




ous spike-waves during slow-wave sleep epilepsy syndrome; Gp, glycoprotein; HS,
E, temporal lobe epilepsy.
her’s exact).
Table 3
The prevalence of CL and b2-GpI antibodies in patients and controls according to seizure frequency.
IgM-CL IgG-CL b2-GpI
Pos (%) OR (95%CI) p Pos (%) OR (95%CI) p Pos (%)
Frequency
Yearly (n=9) 2 (22) 1.1 (0.2–6.1) 0.88 0 NC 0
Monthly (n=27) 12 (44) 3.2 (1.2–8.3) 0.02 3 (11) 0.85 (0.2–3.4) 0.82 3 (11)
Weekly (n=21) 10 (48) 3.6 (1.3–10.3) 0.02 5 (24) 2.1 (0.6–7.2) 0.23 2 (10)
Daily (n=17) 10 (59) 5.7 (1.8–17.7) 0.002 4 (24) 2.1 (0.6–7.8) 0.28 2 (12)
All patients (n=74) 34 (46) 3.4 (1.6–7.1) 0.001 12 (16) 1.3 (0.5–3.3) 0.57 7 (10)*
Controls (n=70) 14 (20) 9 (13) 0
Statistical difference between particular patient group and control group was evaluated using logistic regression analysis (IgM-CL and IgG-CL). Abbreviations: b2-GpI, beta2
glycoprotein I; CI, conﬁdential interval; CL, cardiolipin; IgG, immunoglobulin class G; IgM, immunoglobulin class M; NC, not calculable; OR, odds ratio.
Statistical difference between patients and controls: *, p<0,05; Fisher’s exact).
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increased concomitantly with increasing seizure frequency com-
pared to controls (Table 3). b2-GpI and ANA antibodies were not
signiﬁcantly associated to seizure frequency.
3.2.4. Intellectual disability
To test association between antibody prevalence and intellectual
disability, subnormal, mild and moderate levels of disability were
pooled as a single group (IQ> 35; n = 13), severe as one group (IQ
20–34; n = 30) and profound disability as one group (IQ< 20;
n = 31). The prevalence of positive IgM-CL antibodies increasedwith
increasing intellectual disability (Table 4). IgG-CL antibodies were
also more frequent in profound intellectual disability compared
with controls (Table 4). The prevalence of b2-GpI antibodies
increased signiﬁcantly with increasing intellectual disability (Table
4). ANAantibodieswerenot signiﬁcantly associatedwith the level of
cognitive impairment (data not shown).
3.2.5. Antibody titres
Among 34 IgM-CL positive patients 15 (44%) were regarded as
moderately positive (21–80 MPL units) and within 14 control
subjects 5 (36%) were moderately positive. Other positive patients
and control subjects had low positive titres. Among IgG-CL positive
patients 7 out of 12 (58%) were regarded as moderately positive
(21–80 GPL units), however, in controls, IgG-CL was moderately
positive only in 3 out of 9 subjects (33%). Other patients and control
subjects had low positive titres. Highest detected CL titres
(moderate) were not found to be associated to any speciﬁc
diagnosis or etiology. Observed titres for b2-GpI antibodies were
between 39 and 82 international SGU units.
4. Discussion
In the present study we found that in developmental disorders
manifesting with epilepsy the prevalence of IgM-CL and b2-GpI
antibodies is signiﬁcantly higher compared to healthy bloodTable 4
The prevalence of CL and b2-GpI antibodies in patient groups according to the severity
IgM-CL
Pos (%) OR (95%CI)
Disability
Subnormal–moderate (IQ>35, n=13) 4 (31) 1.8 (0.5–6.6)
Severe (IQ 20–34, n=30) 13 (43) 3.1 (1.2–7.8)
Profound (IQ<20, n=31) 17 (55) 4.9 (1.9–12.2)
All patients (n=74) 34 (46) 3.4 (1.6–7.1)
Controls (n=70) 14 (20)
Statistical difference between particular patient group and control group was tested us
glycoprotein I; CI, conﬁdential interval; CL, cardiolipin; IgG, immunoglobulin class G; I
Statistical difference between patients and controls: *, p<0,05 (Fisher’s exact). Statistidonors. Interestingly, increase in seizure frequency increased
concomitantly the risk for positive IgM-CL antibodies. Finally, we
found that increasing severity of intellectual disability increased
signiﬁcantly the risk for positive IgM-CL, IgG-CL and b2-GpI
antibodies.
Previously, IgG-CL antibodies were found in patients with
recent seizures, but not in patients who were seizure free for a
month prior to sampling.13 In a large population based study by
Ranua et al. authors described that patients with partial epilepsy
with at least one seizure per month were more likely to have
positive IgG-CL antibodies than patients with lower seizure
frequency.14 The authors of these studies suggested that produc-
tion of PL antibodies reﬂects secondary immune system activation
related to seizures. Our results further support this hypothesis.
Whether autoantibodies are associatedwith the developmental
disorders or epilepsy as such cannot be fully evaluated in the
present study since patients with developmental disorder without
epilepsy were not included in the study. However, the prevalence
of CL and b2-GpI antibodies in our patients with developmental
disorder and refractory epilepsy is in accordance with a study in
adult patients with localization related epilepsy.11 We therefore
conclude that epilepsy and seizures is more clearly associatedwith
PL antibodies than developmental disorders as per se.
The pathophysiological relevance of PL antibodies in develop-
mental disorders and refractory epilepsy is controversial. In SLE,
moderate or high titres of CL-IgG are associatedwith seizures.9 SLE
patients with positive IgG-CL antibodies have 3.7 times higher risk
for seizures compared to CL antibody negative patients,10
suggesting that antibodies may indeed decrease seizure threshold
level. PL antibodies have been shown to depolarize neurons in
vitro.15 Moreover, CL antibodies have been described to reduce
gamma-aminobutyric acid (GABA) mediated inhibition of neu-
rons.16 PL antibodies have suggested to cause epilepsy in a few
pediatric patients.17
Impairment of cognitive functions in SLE patients with PL-
antibodies is well documented.8 We found that the prevalence ofof intellectual disability.
IgG-CL b2-GpI
p Pos (%) OR (95%CI) p Pos (%)
0.39 1 (8) 0.6 (0.07–4.9) 0.60 0y
0.02 2 (7) 0.5 (0.1–2.4) 0.37 1 (3)y
0.001 9 (29) 2.7 (0.98–7.9) 0.056 6 (19)y
0.001 12 (16) 1.3 (0.5–3.3) 0.57 7 (10)*
9 (13) 0
ing logistic regression analysis (IgM-CL and IgG-CL). Abbreviations: b2-GpI, beta2
gM, immunoglobulin class M; OR, odds ratio.
cal difference between patient groups: y, p<0,05 (qhi square test).
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with most severe forms of intellectual disability compared to
moderate to subnormal impairment. It can be hypothesized that CL
andb2-GpI antibodiesmay serve asmarkers of secondary neuronal
tissue injury manifesting with cognitive impairment. However,
further studies are needed to conﬁrm our ﬁndings.
Several factors limit the interpretation of our data. Classiﬁca-
tion of patients into smaller heterogeneously sized subgroups
limits the evaluation of antibody prevalence, especially if antibody
prevalence is low (Ig-CL, b2-GpI and ANA). IgM-CL had clearly
highest prevalence both in healthy controls and all patient groups,
enabling most reliable calculations. However, the pathophysiolog-
ical relevance of IgM-CL antibodies in epilepsy is entirely
unknown, and is most likely limited due to its relatively high
prevalence in healthy controls. However, we suggest that
increased IgM-CL prevalence in patients with frequent seizures
reﬂects host’s non-speciﬁc immunological activation as a response
to frequent seizures.
As a conclusion, our results as well as previous data indicate
that developmental disorders with refractory epilepsy are
associatedwith low tomoderate titres of CL andb2-GpI antibodies.
High seizure frequency and especially severe intellectual disability
were signiﬁcantly associated to positive antibody titres. Observed
immunological activation is most likely secondary phenomenon
due to high seizure frequency and neuronal tissue damage.
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